Headache Center Fellowship
Leadership
- Program Director
- Headache Fellowship Program
For Program Information
901 Walnut Street
Suite 400
Philadelphia, PA 19107
The Jefferson Headache Center Fellowship program is dedicated to giving to the trainee the highest quality preparation so that he or she can make contributions to patient care and advance the level of knowledge of headache medicine.
The program will prepare the Fellow for a career in clinical headache practice or academic headache medicine. The Fellow will be exposed to outpatient and inpatient headache patient care, as well as clinical headache research involving epidemiology, Neurophysiology, and therapeutic studies. In addition, an optional pediatric headache rotation is available. Headache medicine is a unique subspecialty of neurology that requires knowledge not previously taught to trainees during their respective residency programs.
The Fellowship program consists of 12 months of training. The trainee will spend most of his or her time in the outpatient and inpatient headache units, but will have ample time to participate in research projects of their choosing. The trainee will see patients 4 days/week, with 2 half days/week devoted to research.
The Headache Center
The Jefferson Headache Center is one of a very few academic headache centers in the country.
In addition to treating patients, the Jefferson Headache Center is a teaching facility that gives residents the highest quality of preparation so that they can make contributions to patient care and advance the level of knowledge of headache medicine.
Publications
- Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
- Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials
- Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
- Cranial Neuralgias
- Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis